AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

Barchart · 2d ago

CEO interview explores Ampligen’s potential to extend survival and improve quality of life as AIM advances toward pivotal development

Access the article here

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.